Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

) in Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL)
Date/Time: June 15, 2013, 5:45PM-7:00PM, Location: Poster Hall, Author: Dr. Anas Younes

International Conference on Malignant Lymphoma in Lugano, Switzerland June 19-22, 2013At the International Conference on Malignant Lymphoma (ICML) there will be three oral presentations and three poster presentations on ibrutinib, and one oral presentation on abexinostat, Pharmacyclics' HDAC inhibitor. One oral presentation in the plenary session will show results using ibrutinib as a monotherapy in R/R CLL patients with deletion 17p as previously reported at AACR earlier this year. One oral presentation will cover the trial results using ibrutinib as a monotherapy in R/R Waldenstrom Macroglobulinemia (WM) patients. The other oral presentation will show the Phase I results using R-CHOP plus ibrutinib in frontline NHL patients similar to the data that will be presented at ASCO and EHA in June, 2013. Two posters are updates from the MD Anderson trial using ibrutinib plus rituximab in high risk CLL patients. An additional poster will show updated results from Pharmacyclics' trial PCYC-1104 with similar data from the oral presentation at EHA in June, 2013. An additional oral presentation will show trial data using the HDAC inhibitor abexinostat in patients with R/R follicular lymphoma.

  • Oral Presentation in Plenary Session (Encore from AACR)
    Single Agent Ibrutinib (PCI-32765) is Highly Effective in Chronic Lymphocytic Leukemia (CLL) Patients with 17p Deletion
    Date/Time: June 19, 2013, 2:40PM – 3:00PM, Locations: Room A, B and Marquee Parco Ciani, Author: Dr. Adrian Wiestner 
  • Oral Presentation
    A Prospective, Multicenter, Phase II Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Patients with Relapsed and Refractory Waldenstrom's Macroglobulinemia 
    Date/Time: June 20, 2013, 4:20PM - 4:35PM, Location: Room A and Marquee, Author: Dr. Stev
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    11. Hospira Reports First-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
    (Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
    (Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
    Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
    ... breakthroughs in brain,research and technology may have a great ... to scientists visiting the US Senate today. At the,invitation ... Pensions,(HELP) researchers from Posit Science, a leading provider of ... lecture and,part hands-on science fair., "Many believe that ...
    ... Society Of Clinical Psychopharmacology ... Meeting, ... Assignee of the assets of Spherics, Inc. ("Spherics") for,the benefit of creditors, ... a sealed bid auction on October 10,2008., Topamax(R) produces adverse effects ...
    Cached Medicine Technology:Senate Told Brain Technology Can Impact Public Policy 2Senate Told Brain Technology Can Impact Public Policy 3Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R) 2
    (Date:7/10/2014)... is one of the top public health concerns in ... 2-19 classified as obese as of 2012. As health ... have taken to Twitter to discuss the problem. , ... assistant professor at the Brown School at Washington University ... #childhoodobesity in tweets to track Twitter conversations about the ...
    (Date:7/10/2014)... medical imaging far outweigh the risks when children receive ... Right Radiation Dose. However, overuse and misuse of imaging ... a collaborative effort to ensure a national protocol is ... Journal of Patient Safety , calls for the ... Accreditation Commission, and the Centers for Medicare & Medicaid ...
    (Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
    (Date:7/10/2014)... Men who experience hot flashes are unlikely to ... from their silent suffering if they are willing ... a Baylor University case study., After seven weeks of ... hot flashes following prostate cancer surgery showed a drastic ... impressive improvement in sleep quality, according to the study., ...
    (Date:7/9/2014)... a small increased risk of prostate cancer, and a ... to a new study from Harvard School of Public ... even among men who received regular PSA screening, suggesting ... by diagnostic bias. It is the largest and most ... between vasectomy and prostate cancer. , The study appears ...
    Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Vasectomy may increase risk of aggressive prostate cancer 2
    ... /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: ... in the People,s Republic,of China, held a Board ... which a new,Board member was appointed to serve ... an Audit Committee and a Compensation Committee were ...
    ... 23 Laura Kolkman, President,Mosaica Partners, a ... been selected to serve as Chair of ... Healthcare Information,Exchange (HIE) Steering Committee., The ... all HIE,stakeholders including providers, payers, vendors, consultants ...
    ... new survey of employers by the,non-profit Midwest Business Group ... the Smoke-free Illinois Act*, helps companies and,their employees overcome ... a challenge., MBGH conducted its second annual Smoking ... level of employer involvement in reducing tobacco,use among workers. ...
    ... up on innuendo and social cues is a central component ... to determine another person,s intentions in a social interaction. New ... mechanisms that are responsible for such social difficulties in autism, ... all of us. , According to the study, which ...
    ... by Edison Pharma , ... Boston (PRWEB) July 23, ... Guide to MITO Management, a comprehensive online resource designed to assist ... affected by mitochondrial disease. The Clinicians Symptom Guide to MITO Management ...
    ... of free web meeting software has recently added advanced features like shared ... far, these features were only available for a high cost with paid ... Desktop Service, which lets you log into your home or office PC ... ...
    Cached Medicine News:Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 3Health News:Autism's social struggles due to disrupted communication networks in brain 2Health News:MitoAction Develops On-Line Resource for Mitochondrial Disease Care Providers 2Health News:How to Conduct Free Web Meetings and Remote Desktop? 2
    ... Cardiology specific EMR / PM system ... nationwide,enabling more effective patient care decisions.,AcerMed's ... clinicians with critical information on a ... care.,Our Cardiology specific clinical pathways have ...
    ... in Critical Care & Emergency Medicine. ... cordless, and simple to use device which ... of the pupillary light reflex (PLR). Now ... which are not discernable to the naked ...
    ... Metrikas pager-sized A1cNow ... technology to provide healthcare ... access to quantitative A1C ... indicator of diabetes management ...
    ... VenaCure Laser Vein Treatment. It is estimated ... worldwide have varicose veins. In the United States, ... of 60 suffer from painful and unsightly venous ... the capabilities of vascular therapy for the treatment ...
    Medicine Products: